Eagle Genomics, Earlham Institute in UK collaborate to advance microbiome research

Photo © AdobeStock.com/ denisismagilov

Eagle Genomics (Cambridge, UK), creator of network life sciences platforms, announced a new partnership with the Earlham Institute (Norwich, UK) to further tools for analyzing microbiome research data.

The Earlham Institute is a “hub for innovative bioinformatics through research, analysis, and interpretation of multiple, complex data sets.” The Institute focuses on “developing and testing laboratory methods and computational biology pipelines to study microbial communities," developing tools and datasets for bioinformaticians.

Meanwhile, Eagle Genomics leverages its e[datascientist] platform, which uses network science and artificial intelligence tools to innovate how complex, multidimensional microbiome data is analyzed. The e[datascientist] platform “applies network science to multidimensional life sciences data, including environmental and clinical metagenomes for multi-omics analysis,” helping to accelerate research and development on the human microbiome, including for the generation of product claims, for industries such as agritech, food, healthcare, personal care, and beauty.

Together, the groups will collaborate on R&D, consultancy work, licensing, and applying the e[datascientist] platform across both academia and industry. The partnership could result in enhanced research on the “classification and genome reconstruction in complex environments, biological signaling network resources for human and model organisms, global patterns for antimicrobial resistance found in microbes, and investigating the persistence and evolution of human-associated microbes,” the firms said in a press release.

Liliya Serazetdinova, PhD, head of business development and impact at the Earlham Institute, said the press release, “This partnership is part of a big data revolution in terms of how multi-omics data will be accessed and analyzed . . . Eagle Genomics’ e[datascientist] platform gives our scientists the opportunity to share their work more widely, establish new connections, and use it as a testing ground—interrogating and integrating new datasets, as well as developing new tools and pipelines—to further advance our research and apply to the biotech industry. We’re really excited to be working with Eagle Genomics and look forward to seeing how this platform evolves, and involves more partners in the coming months.”